Cargando…

Symposium Abstract: ANCIPS 2022: Metabolic abnormalities in Depression

Major depression and bipolar disorder are common conditions with substantial negative consequences for sufferers. Understanding the biological changes associated with these conditions is a major research priority, and a better understanding of their biological basis could lead to improved diagnosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Hans*, Gagan, Das, Nileshwar, Sharma, Uma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129695/
http://dx.doi.org/10.4103/0019-5545.341617
_version_ 1784712818611716096
author Hans*, Gagan
Das, Nileshwar
Sharma, Uma
author_facet Hans*, Gagan
Das, Nileshwar
Sharma, Uma
author_sort Hans*, Gagan
collection PubMed
description Major depression and bipolar disorder are common conditions with substantial negative consequences for sufferers. Understanding the biological changes associated with these conditions is a major research priority, and a better understanding of their biological basis could lead to improved diagnosis and treatment. There is growing interest in the development of precision medicine algorithms with the aim of tailoring treatment strategies to individual patients according to unique biological signatures. This biomarker-based approach to precision prescribing has the potential to improve therapeutic response, minimize adverse reactions, and reduce time to symptomatic relief. However, few validated biological targets for treatment response prediction in depression have been identified to date. Biomarkers derived from neuroimaging data are potentially important contributors to the goal of guiding treatment selection using clinical and bio-typing data. Information on brain structure and function may be used to predict response versus non-response to various treatments. Ignited by the observation of a rapid antidepressant effect of the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine, the glutamate system has emerged as a leading focus for novel drug discovery for depression and other mood disorders. Over the last two decades, neuroimaging has brought a deeper understanding of neurobiological alterations associated with these conditions, and researchers are moving towards developing these methods to diagnose and treat affective disorders. This research has been aided by developments in magnetic resonance spectroscopy (MRS), a method that allows non-invasive measurement of glutamate and glutamine levels in vivo. Glutamate and glutamine levels are typically found to be reduced in unipolar depression, most notably in prefrontal regions such as the anterior cingulate cortex, while studies in bipolar disorder suggests an increase in glutamate in this region.
format Online
Article
Text
id pubmed-9129695
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-91296952022-05-25 Symposium Abstract: ANCIPS 2022: Metabolic abnormalities in Depression Hans*, Gagan Das, Nileshwar Sharma, Uma Indian J Psychiatry Free Papers Compiled Major depression and bipolar disorder are common conditions with substantial negative consequences for sufferers. Understanding the biological changes associated with these conditions is a major research priority, and a better understanding of their biological basis could lead to improved diagnosis and treatment. There is growing interest in the development of precision medicine algorithms with the aim of tailoring treatment strategies to individual patients according to unique biological signatures. This biomarker-based approach to precision prescribing has the potential to improve therapeutic response, minimize adverse reactions, and reduce time to symptomatic relief. However, few validated biological targets for treatment response prediction in depression have been identified to date. Biomarkers derived from neuroimaging data are potentially important contributors to the goal of guiding treatment selection using clinical and bio-typing data. Information on brain structure and function may be used to predict response versus non-response to various treatments. Ignited by the observation of a rapid antidepressant effect of the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine, the glutamate system has emerged as a leading focus for novel drug discovery for depression and other mood disorders. Over the last two decades, neuroimaging has brought a deeper understanding of neurobiological alterations associated with these conditions, and researchers are moving towards developing these methods to diagnose and treat affective disorders. This research has been aided by developments in magnetic resonance spectroscopy (MRS), a method that allows non-invasive measurement of glutamate and glutamine levels in vivo. Glutamate and glutamine levels are typically found to be reduced in unipolar depression, most notably in prefrontal regions such as the anterior cingulate cortex, while studies in bipolar disorder suggests an increase in glutamate in this region. Wolters Kluwer - Medknow 2022-03 2022-03-24 /pmc/articles/PMC9129695/ http://dx.doi.org/10.4103/0019-5545.341617 Text en Copyright: © 2022 Indian Journal of Psychiatry https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Free Papers Compiled
Hans*, Gagan
Das, Nileshwar
Sharma, Uma
Symposium Abstract: ANCIPS 2022: Metabolic abnormalities in Depression
title Symposium Abstract: ANCIPS 2022: Metabolic abnormalities in Depression
title_full Symposium Abstract: ANCIPS 2022: Metabolic abnormalities in Depression
title_fullStr Symposium Abstract: ANCIPS 2022: Metabolic abnormalities in Depression
title_full_unstemmed Symposium Abstract: ANCIPS 2022: Metabolic abnormalities in Depression
title_short Symposium Abstract: ANCIPS 2022: Metabolic abnormalities in Depression
title_sort symposium abstract: ancips 2022: metabolic abnormalities in depression
topic Free Papers Compiled
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129695/
http://dx.doi.org/10.4103/0019-5545.341617
work_keys_str_mv AT hansgagan symposiumabstractancips2022metabolicabnormalitiesindepression
AT dasnileshwar symposiumabstractancips2022metabolicabnormalitiesindepression
AT sharmauma symposiumabstractancips2022metabolicabnormalitiesindepression